Sher E, Denis-Donini S, Zanini A, Bisiani C, Clementi F
CNR Center of Cytopharmacology, Department of Medical Pharmacology, University of Milan, Italy.
J Cell Biol. 1989 Jun;108(6):2291-300. doi: 10.1083/jcb.108.6.2291.
IMR-32 human neuroblastoma cells are unable to release [3H]dopamine in response to secretagogues. However, they express a normal complement of membrane receptors and ion channels which are efficiently coupled to second messenger production. In the present study we took advantage of the ability of this cell line to differentiate in vitro in the presence of either dibutyrryl-cAMP or 5-bromodeoxyuridine, to analyze any developmentally regulated changes in its secretory properties. Uptake, storage, and release of [3H]dopamine were studied biochemically and by autoradiography. The calcium ionophore ionomycin, phorbol 12-myristate 13-acetate and the presynaptic acting neurotoxin alpha-latrotoxin were used in both control and differentiated cells as secretagogue agents. The presence of secretory organelles was investigated by electron microscopy; the expression of secretory organelle markers, such as chromogranin/secretogranin proteins (secretory proteins) and synaptophysin (membrane protein), was detected by Western blotting and immunofluorescence. The results obtained indicate that IMR-32 cells acquire regulated secretory properties after in vitro drug-induced differentiation: (a) they assemble "de novo" secretory organelles, as revealed by electron microscopy and detection of secretory organelle markers, and (b) they are able to store [3H]dopamine and to release the neurotransmitter in response to secretagogue stimuli. Furthermore, secretagogue sensitivity was found to be different, depending on the differentiating agent. In fact, dibutyrryl-cAMP treated cells release [3H]dopamine in response to alpha-latrotoxin, but not in response to ionomycin, whereas 5-bromodeoxyuridine treated cells release the neurotransmitter in response to both secretagogues. All together these results suggest that IMR-32 cells represent an adequate model for studying the development of the secretory apparatus in cultured human neurons.
IMR - 32人神经母细胞瘤细胞不能对促分泌剂作出反应而释放[3H]多巴胺。然而,它们表达正常的膜受体和离子通道,这些受体和通道能有效地与第二信使的产生相偶联。在本研究中,我们利用该细胞系在二丁酰环磷腺苷(dibutyrryl - cAMP)或5 - 溴脱氧尿苷存在下进行体外分化的能力,来分析其分泌特性中任何受发育调控的变化。通过生化方法和放射自显影研究了[3H]多巴胺的摄取、储存和释放。在对照细胞和分化细胞中均使用钙离子载体离子霉素、佛波酯12 - 肉豆蔻酸酯13 - 乙酸酯以及突触前作用的神经毒素α - latrotoxin作为促分泌剂。通过电子显微镜研究分泌细胞器的存在;通过蛋白质免疫印迹和免疫荧光检测分泌细胞器标志物的表达,如嗜铬粒蛋白/分泌粒蛋白(分泌蛋白)和突触素(膜蛋白)。所获得的结果表明,IMR - 32细胞在体外药物诱导分化后获得了受调控的分泌特性:(a)如电子显微镜和分泌细胞器标志物检测所显示的,它们“重新”装配分泌细胞器;(b)它们能够储存[3H]多巴胺并对促分泌剂刺激作出反应而释放神经递质。此外,发现促分泌剂敏感性因分化剂而异。实际上,经二丁酰环磷腺苷处理的细胞对α - latrotoxin作出反应而释放[3H]多巴胺,但对离子霉素无反应,而经5 - 溴脱氧尿苷处理的细胞对两种促分泌剂均作出反应而释放神经递质。所有这些结果表明,IMR - 32细胞是研究培养的人神经元中分泌装置发育的合适模型。